HB

HB Therapeutics is a biotechnology company specializing in the development of targeted protein degradation (TPD) therapies for neurodegenerative and intractable diseases. The company utilizes its proprietary AUTOTAC (Autophagy-Targeting Chimera) platform, which leverages the cell's natural autophagy-lysosome pathway to selectively degrade disease-causing protein aggregates and organelles. Unlike traditional PROTACs that rely on the ubiquitin-proteasome system, HB Therapeutics' approach is designed to target larger protein inclusions and non-proteinaceous targets. Their current pipeline focuses on high-impact targets such as Tau and Alpha-synuclein to address conditions like Alzheimer's and Parkinson's disease.